Effects of declining sorafenib levels and dose on acquired reversible resistance and toxicity in hepatocellular carcinoma Elizabeth A. Kuczynski, Christina.

Slides:

Advertisements

Similar presentations

EC917 Eva Gallardo, MD Medical Manager, Biocompatibles UK Drug Eluting Bead: Future Product Applications.

Advertisements

AntibodyCatalog #Company Desminab15200Abcam Smooth muscle actinab5694Abcam S100ab868Abcam Cytokeration(AE1/AE3)ab961Abcam P53sc-6243Santa Cruz Calponinab46794Abcam.

Supplementary Figure 1. The effect of 17-DMAG on the growth of lung cancer cells with Met amplification Tumor cells were continuously treated with increasing.

Figure 1 B D DOX ( μ M) C Cell Proliferation (% Con) MCF-7MCF-7/DOX DOX ( μ M) 0.03% 38.79% 0.15% 0.10% 0.20% 0.05%

Supplementary Figure S1 Inhibition of AKT and S6 phosphorylation. After 4 h treatment with 1 µM of GDC-0941, EVSA-T parental, resistant Clone1, Clone2,

Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Immune Response During Therapy With Cisplatin or Radiation.

Date of download: 6/22/2016 Copyright © 2016 American Medical Association. All rights reserved. From: An In Vivo Evaluation of Docetaxel Delivered Intratumorally.

Supplementary Figure S1 a

Volume 66, Issue 6, Pages (June 2017)

Nicotinamide Phosphoribosyltransferase: A Potent Therapeutic Target in Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor-Gene Mutation

B A P-AXL P-AXL AXL AXL P-MET P-MET MET MET P-Akt-473 P-Akt-473 AKT

C/EBPα inhibits hepatocellular carcinoma by reducing Notch3/Hes1/p27 cascades Yi-Chao Shi, Hong Zhao, Chuan Yin, Xin Zeng, Qing Zhang, Wen-Ping Xu, Ji.

Volume 63, Issue 1, Pages (July 2015)

PARPi-FL - a Fluorescent PARP1 Inhibitor for Glioblastoma Imaging

Fig. 1. APG increased the sensitivity of BEL-7402/ADM cells to ADM

Novel Pretreatment Scoring Incorporating C-reactive Protein to Predict Overall Survival in Advanced Hepatocellular Carcinoma with Sorafenib Treatment Liver.

Drug concentration (μM)

Figure 3. Sensitivity of the gastric carcinoma cell line N87 for trastuzumab in comparison with the breast cancer cell line SKBR-3. (A) Dose–response curves.

Supplementary Figure 1 Lapatinib nM mM pEGFR MDA-MB231 EGFR pEGFR

Inhibition of FGFR fusion kinase activity repressed tumor growth in a mouse xenograft model. Inhibition of FGFR fusion kinase activity repressed tumor.

Molecular Therapy - Nucleic Acids

Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.

Volume 152, Issue 5, Pages (April 2017)

State of the Art in HCC: Immune Checkpoint Modulation

Yunguang Sun, PhD, Luigi Moretti, MD, Nicholas J

Volume 44, Issue 3, Pages (March 2006)

The Role of PDGFR-β Activation in Acquired Resistance to IGF-1R Blockade in Preclinical Models of Rhabdomyosarcoma Christine M. Heske, Choh Yeung, Arnulfo.

Volume 151, Issue 2, Pages e12 (August 2016)

A B A B C Supplementary Fig. 8 Supplementary Fig. 9

Volume 144, Issue 2, Pages (February 2013)

Cell Physiol Biochem 2016;39: DOI: /

The Zinc Ionophore PCI-5002 Radiosensitizes Non-small Cell Lung Cancer Cells by Enhancing Autophagic Cell Death Kwang Woon Kim, PhD, Christina K. Speirs,

Volume 28, Issue 3, Pages (September 2015)

Volume 19, Issue 3, Pages (March 2017)

Volume 44, Issue 1, Pages (January 2006)

Volume 67, Issue 6, Pages (December 2017)

Volume 131, Issue 5, Pages (November 2006)

Volume 143, Issue 6, Pages e5 (December 2012)

Correction Journal of the American College of Surgeons

Volume 18, Issue 1, Pages (July 2010)

Tumor development of poorly immunogenic LLC and B16F10 cells modified to produce GM-CSF was markedly inhibited. Tumor development of poorly immunogenic.

Volume 131, Issue 5, Pages (November 2006)

Figure 2S (Supplementary Data)

Volume 23, Issue 1, Pages (January 2013)

Volume 29, Issue 4, Pages (April 2016)

PDGFRβ is dispensable for EGFRvIII-driven GBM growth but is required for the optimal growth of EGFR-inhibited tumors. PDGFRβ is dispensable for EGFRvIII-driven.

AT-101, a Pan-Bcl-2 Inhibitor, Leads to Radiosensitization of Non-small Cell Lung Cancer Luigi Moretti, MD, Bo Li, MD, Kwang Woon Kim, PhD, Heidi Chen,

Interleukin-22 Is Frequently Expressed in Small- and Large-Cell Lung Cancer and Promotes Growth in Chemotherapy-Resistant Cancer Cells Sebastian Kobold,

Molecular Therapy - Nucleic Acids

Treatment with BLU9931 leads to tumor regression in the FGF19-amplified Hep 3B liver cancer model. Treatment with BLU9931 leads to tumor regression in.

Lovastatin Sensitizes Lung Cancer Cells to Ionizing Radiation: Modulation of Molecular Pathways of Radioresistance and Tumor Suppression Toran Sanli,

The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma cells. The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma.

Volume 10, Issue 1, Pages (July 2006)

Supplementary Figure 1. Structure of amlexanox

BMP4 Upregulation Is Associated with Acquired Drug Resistance and Fatty Acid Metabolism in EGFR-Mutant Non-Small-Cell Lung Cancer Cells Duc-Hiep Bach,

Covering the Cover Gastroenterology

Fig. 8 SQLE inhibitor terbinafine suppresses NAFLD-HCC growth in vitro and in vivo. SQLE inhibitor terbinafine suppresses NAFLD-HCC growth in vitro and.

Histone Deacetylase Inhibitor Romidepsin Enhances Anti-Tumor Effect of Erlotinib in Non-small Cell Lung Cancer (NSCLC) Cell Lines Wei Zhang, PhD, Michael.

Volume 26, Issue 2, Pages (August 2014)

Volume 15, Issue 3, Pages (March 2009)

A B C D Supplementary Figure S1 UMSCC1 Plateau: 24 hr Pre-Treatment

Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular.

Pharmacologic inhibition of eIF5A hypusination sensitizes KRas-driven tumor cells to MEK and KRas inhibition. Pharmacologic inhibition of eIF5A hypusination.

pERK ERK pSTAT1 STAT1 pSTAT3 STAT3 pAKT AKT

Single-Dose Neoadjuvant AKT Pathway Inhibitor Reduces Growth of Hepatocellular Carcinoma after Laser Thermal Ablation in a Small Animal Model Neoadjuvant PI3K/mTOR/AKT inhibitor prior.

Volume 66, Issue 3, Pages (March 2017)

Ganetespib suppresses tumor growth and extends survival in ALK+ NSCLC xenografts. Ganetespib suppresses tumor growth and extends survival in ALK+ NSCLC.

Ceritinib is a potent ALK inhibitor in crizotinib-naïve models.

In vivo effect of KIN-193 on PTEN-deficient tumors.

Supplementary Figure 1: AGS-22M6E ADC specific localization in tumor xenografts. AG-B1 tumor pieces were implanted in ICR-SCID mice subcutaneously.

Presentation transcript:

Effects of declining sorafenib levels and dose on acquired reversible resistance and toxicity in hepatocellular carcinoma Elizabeth A. Kuczynski, Christina R. Lee, Shan Man, Eric Chen, Robert S. Kerbel SUPPLEMENTARY FIGURES S1-5

C Hep3B-hCG parental Hep3B-hCG- R1 Hep3B-hCG- R2 D A B EGF Sorafenib P-ERK ERK ParentalR E F G Invasion Proliferation Tumor growth (hCG) Clonogenic Survival hCG: Orthotopic Transfer hCG: Subcutaneous Transfer Supplementary Figure S1 IC50: 3.03µM (P), 2.92µM (R1), 2.36µM (R2)

Supplementary Figure S2 B hCG for Drug Level Assessment A PlasmaTumor *

hCG: 65 Day Sorafenib Pre- Conditioned Mice A B Supplementary Figure S3 +2d implant, +5d treat hCG: Indicator Group of SCID HCC mice p=0.742 p=0.965 P= C

Supplementary Figure S4 Weight Loss: HCC vs. Tumor-Free F G p=0.266 Survival: HCC vs. Tumor-Free D E ** Tumor + Liver Weight p=0.600 Survival: Dose escalation (30 mg/kg) p=0.165 p=0.285 B hCG: Dose Escalation Early vs. Late Progressors *p= Sorafenib concentrations: day 14 C p=0.202 p=0.152 p= A

A C Liver Lysates - Tumor-Free Control* Sensitive Resistant Escalated Liver lysates - HCC SensitiveResistantEscalatedControl P-STAT3 STAT3 P-STAT3 STAT3 Supplementary Figure S5 D ControlSensitiveResistantEscalated CAIX Actin ControlSensitive Resistant Escalated P-PDGFRβ PDGFRβ Tumor Lysates B P-ERK ERK